NASDAQ · Health Care

SOPHIA GENETICS SA SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
  • Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland.
  • The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom.
  • The company was incorporated in 2011 and is based in Rolle, Switzerland.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within health information services?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -11.62% Buyback -3.62%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Akre Capital Management Chuck Akre 0.3% $18.4M 2026-03-31

Recent trading changes over the last 1 quarters

Net buyers 0 Last 1 13F filing periods
Net reducers 0 Last 1 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $0 Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares 0.0% +0 / 3,719,140
Akre Capital Management Chuck Akre 1 filing periods
13F 2026-03-31 Filed 2026-05-14
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 3,719,140 Last 1 periods +0 (0.0%) Total shares 3,719,140 Value $18.4M

Recent mentions

No public mentions.